Abbvie Header week 48

Abbvie Header week 48

X

[{"orgOrder":0,"company":"Healios K.K","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Healios K.K. to Highlight Its Novel Approach in Regenerative Medicine at the Upcoming 38th Annual J.P. Morgan Healthcare Conference and Biotech Showcase in San Francisco, CA","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Healios to Enroll COVID-19 Patients in Phase II Off-the-Shelf Cell Therapy Program for ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Athersys","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Athersys Announces Cooperation Agreement With HEALIOS K.K.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Athersys","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athersys Reports That Its Partner, HEALIOS K.K., Provides Updates on MultiStem\u00ae Clinical Programs in Japan","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III"}]

Find Clinical Drug Pipeline Developments & Deals by Healios K.K

Healios K.K
Developments
Full Screen View

Healios K.K

About, Contact Details

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

No Presentations

VIDEO(s)

No Video

DIGITAL CONTENT

4 News

4 News

DEVELOPMENTS

4 Drug(s) in Development

4 Drug(s) in Development

Developments

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Therapeutic Area

filter

Study Phase

Active Filter(s):

Filters

Reset Filter

All Developments

Companies By Therapeutic Area

Development Status

Healios K.K

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Athersys Reports That Its Partner, HEALIOS K.K., Provides Updates on MultiStem® Clinical Programs in Japan

Details:

Healios reported that last patient in its Phase 2/3 TREASURE study, evaluating MultiStem, a patented regenerative medicine product for the treatment of ischemic stroke, completed the 365-day follow-up visit.

Lead Product(s): Invimestrocel

Therapeutic Area: Cardiology/Vascular Diseases Product Name: MultiStem

Highest Development Status: Phase III Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Athersys

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 04, 2022

ASK
US

Upload
your Pipeline Activity

Healios K.K

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Athersys Announces Cooperation Agreement With HEALIOS K.K.

Details:

This agreement will enable both Athersys and Healios to focus on advancing their late-stage programs for MultiStem, including preparing for top line results from Healios’ TREASURE trial for stroke and ONE-BRIDGE trial for ARDS, which is expected this year.

Lead Product(s): MultiStem

Therapeutic Area: Neurology Product Name: HLCM051

Highest Development Status: Phase III Product Type: Cell and Gene therapy

Recipient: Athersys

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement February 16, 2021

ASK
US

Upload
your Pipeline Activity

Healios K.K

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Healios to Enroll COVID-19 Patients in Phase II Off-the-Shelf Cell Therapy Program for ARDS

Details:

HEALIOS K.K continues to make enrolment progress in its ONE-BRIDGE study, a phase II clinical trial in Japan evaluating the safety and efficacy of HLCM051.

Lead Product(s): HLCM051

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 14, 2020

ASK
US

Upload
your Pipeline Activity

Healios K.K

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Healios K.K. to Highlight Its Novel Approach in Regenerative Medicine at the Upcoming 38th Annual J.P. Morgan Healthcare Conference and Biotech Showcase in San Francisco, C...

Details:

The SSC candidate of Healios (HLCM051) is in an ischemic stroke pivotal phase 2/3 trial in Japan in which it offers the potential to provide effective treatment over a much longer treatment window.

Lead Product(s): HLCM051

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 09, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY